Wockhardt is currently trading at Rs. 602.80, up by 30.40 points or 5.31% from its previous closing of Rs. 572.40 on the BSE.
The scrip opened at Rs. 572.05 and has touched a high and low of Rs. 617.80 and Rs. 572.05 respectively. So far 6,24,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1210.00 on 10-Jun-2013 and a 52 week low of Rs. 336.60 on 16-Dec-2013.
Last one week high and low of the scrip stood at Rs. 617.80 and Rs. 568.00 respectively. The current market cap of the company is Rs. 6,637.00 crore.
The promoters holding in the company stood at 74.70% while Institutions and Non-Institutions held 7.84% and 17.32% respectively.
Wockhardt USA Inc, a subsidiary of Wockhardt is voluntarily recalling 8,712 bottles of anti-hypertension drug Metoprolol Succinate extended-release tablets in the US market following failure of a dissolution test. The withdrawal was classified as a Class-II recall, which the FDA defines as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |